- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06663319
Une étude du JNJ-89402638 pour le cancer colorectal métastatique
Une étude de phase I du JNJ-89402638 pour le cancer colorectal métastatique non résécable
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Contact
- Numéro de téléphone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lieux d'étude
-
-
-
Seoul, Corée du Sud, 05505
- Recrutement
- Asan Medical Center
-
Seoul, Corée du Sud, 03722
- Recrutement
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Hosp Univ Vall D Hebron
-
Madrid, Espagne, 28041
- Recrutement
- Hosp. Univ. 12 de Octubre
-
Madrid, Espagne, 28040
- Recrutement
- Hosp Univ Fund Jimenez Diaz
-
Madrid, Espagne, 28050
- Recrutement
- Hosp Univ Hm Sanchinarro
-
-
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85719
- Recrutement
- University of Arizona Cancer Center
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- University of Colorado Denver Anschultz Medical Campus
-
-
Florida
-
Sarasota, Florida, États-Unis, 34232
- Recrutement
- Florida Cancer Specialists
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46256
- Recrutement
- Community Health Network
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49546
- Recrutement
- Start Midwest
-
-
Washington
-
Seattle, Washington, États-Unis, 98104
- Recrutement
- Swedish Cancer Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
For Part 1 (dose escalation), Part 2 (Arm A [JNJ-89402638 monotherapy]): Have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma (CRC) progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting; For Part 2 Arm B (JNJ-89402638 + bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of CRC progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting; For Part 2 Arm C (JNJ-89402638 + FOLFOX/bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC progressing after 1 or more prior lines of standard therapy in the metastatic/unresectable setting. Participants must have previously received a fluoropyrimidine and irinotecan doublet (such as FOLFIRI); For Part 2 Arm D (JNJ-89402638 + FOLFIRI/bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of MSS or pMMR CRC progressing after 1 prior line of standard therapy in the metastatic/unresectable setting. Must not have received irinotecan previously for metastatic disease; For Part 2 Arm E (JNJ-89402638 monotherapy in mGAC): Have histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressing after 1 or more prior lines of standard therapy in the metastatic/unresectable setting
-
Have evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) version 1.1
- Part 1: Must have either measurable or evaluable disease
- Part 2: Must have at least 1 measurable lesion
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
-
Have an estimated or measured glomerular filtration rate (GFR) greater than or equal to (>=) 30 milliliter per minute (mL/min) based on modification of diet in renal disease (MDRD) 4-variable formula
Exclusion Criteria:
- Active (new or progressive) brain metastases, leptomeningeal disease, or untreated spinal cord compression
- Toxicity from prior anticancer therapy that has not resolved to Grade less than or equal to (<=)1 (except alopecia, vitiligo, Grade <= 2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement). For Part 2 Arm C: Grade 2 or higher peripheral neuropathy is considered exclusionary
- Has a prior or concurrent second malignancy (other than the disease under study) unless natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Received glucocorticoids (doses >10 mg/day prednisone or equivalent) within 7 days prior to the first dose of study drug
- Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment or within 4 weeks after the last dose of study treatment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1 (Dose Expansion)
Participants with unresectable metastatic colorectal adenocarcinoma (mCRC) will receive JNJ-89402638 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially until the recommended Phase 2 Dose(s) (RP2D) and optimal route(s) of administration for JNJ-89402638 monotherapy have been identified. |
JNJ-89402638 will be administered. |
|
Expérimental: Part 2 (Dose Expansion): Arm A
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) and route as determined in Part 1 as a monotherapy. |
JNJ-89402638 will be administered. |
|
Expérimental: Part 2 (Dose Expansion): Arm B
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 along with bevacizumab or biosimilar. |
JNJ-89402638 will be administered. Bevacizumab or biosimilar will be administered. |
|
Expérimental: Part 2 (Dose Expansion): Arm C
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 along with bevacizumab or biosimilar and FOLFOX. |
JNJ-89402638 will be administered. Bevacizumab or biosimilar will be administered. Chemotherapy agent FOLFOX will be administered. |
|
Expérimental: Part 2 (Dose Expansion): Arm D
Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 in combination with bevacizumab or biosimilar and FOLFIRI. |
JNJ-89402638 will be administered. Bevacizumab or biosimilar will be administered. Chemotherapy agent FOLFIRI will be administered. |
|
Expérimental: Part 2 (Dose Expansion): Arm E
Participants with metastatic gastric adenocarcinoma (mGAC) will receive JNJ-89402638 at the RP2D(s) and route as determined in Part 1. |
JNJ-89402638 will be administered. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity
Délai: From Baseline up to approximately 24 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded per American Society for Transplantation and Cellular Therapy (ASTCT) consensus. |
From Baseline up to approximately 24 months
|
|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
Délai: From Baseline up to 28 days
|
The DLTs are specific adverse events including high grade hematologic or non-hematologic toxicities. |
From Baseline up to 28 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1 and Part 2: Serum Concentration for JNJ-89402638
Délai: Up to approximately 24 months
|
Serum Concentration for JNJ-89402638 will be reported. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Maximum Serum Concentration (Cmax) of JNJ-89402638
Délai: Up to approximately 24 months
|
Cmax of JNJ-89402638 will be reported. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Minimum Serum Concentration (Cmin) of JNJ-89402638
Délai: Up to approximately 24 months
|
Cmin of JNJ-89402638 will be reported. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-89402638
Délai: Up to approximately 24 months
|
Tmax of JNJ-89402638 will be reported. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Area Under the Serum Concentration-time Curve (AUC) of JNJ-89402638
Délai: Up to approximately 24 months
|
AUC of JNJ-89402638 will be reported. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Number of Participants with Presence of Anti-JNJ-89402638 Antibodies
Délai: Up to approximately 24 months
|
Participants with anti-JNJ-89402638 antibodies will be reported. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Overall Response (OR)
Délai: Up to approximately 24 months
|
Overall response is best response of complete response (CR) or partial response (PR), assessed according to response evaluation criteria in solid tumors (RECIST) version 1.1. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Complete Response (CR)
Délai: Up to approximately 24 months
|
Complete response is defined as a best response of CR assessed according to RECIST version 1.1. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Time to Response (TTR)
Délai: Up to approximately 24 months
|
TTR is defined for participants who achieved an OR from the time of the first dose of study treatment to the first response of PR or better as assessed according to RECIST version 1.1. |
Up to approximately 24 months
|
|
Part 1 and Part 2: Duration of Response (DOR)
Délai: Up to approximately 24 months
|
DOR is defined for participants who achieved an OR in the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease or death due to any cause, whichever occurs first, as assessed according to RECIST version 1.1 |
Up to approximately 24 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies du côlon
- Tumeurs colorectales
- Tumeurs gastro-intestinales
- Acides aminés, peptides et protéines
- Protéines
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Bévacizumab
- Protocole Folfox
- Protocole IFL
Autres numéros d'identification d'étude
- 89402638GIC1001
- 2024-516526-66-00 (Identificateur de registre: EUCT number)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .